{"id":"NCT00882362","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","officialTitle":"Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2009-04-16","resultsPosted":"2014-02-10","lastUpdate":"2014-02-10"},"enrollment":155,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"OPC-14597 (Aripiprazole)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor (SNRI), in subjects with major depressive disorder.","primaryOutcome":{"measure":"Montgomery-Asberg Depression Rating Scale (MADRS)","timeFrame":"Baseline(Day 1), Week52 or at discontinuation","effectByArm":[{"arm":"Continuing Subjects","deltaMin":-4.6,"sd":0.8},{"arm":"Newly Entering Subjects","deltaMin":-10.5,"sd":1.9}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":122},"commonTop":["Nasopharyngitis","Akathisia","Weight Increased","Somnolence","Tremor"]}}